Cigogne Management SA Makes New Investment in Grifols, S.A. (NASDAQ:GRFS)

Cigogne Management SA purchased a new stake in Grifols, S.A. (NASDAQ:GRFS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 238,928 shares of the biotechnology company's stock, valued at approximately $1,778,000. Grifols accounts for 1.1% of Cigogne Management SA's investment portfolio, making the stock its 29th biggest holding.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. GAMMA Investing LLC lifted its position in shares of Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock valued at $37,000 after acquiring an additional 1,527 shares during the last quarter. HighTower Advisors LLC raised its position in shares of Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company's stock worth $123,000 after purchasing an additional 1,546 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Grifols by 5.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock valued at $247,000 after purchasing an additional 1,657 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Grifols by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company's stock valued at $192,000 after purchasing an additional 2,403 shares during the period. Finally, R Squared Ltd purchased a new position in Grifols in the 4th quarter worth about $28,000.

Grifols Stock Down 0.8 %

Shares of GRFS stock traded down $0.06 on Monday, reaching $7.15. 967,876 shares of the company's stock traded hands, compared to its average volume of 1,208,715. The business's 50 day moving average price is $7.47 and its two-hundred day moving average price is $7.75. The company has a market capitalization of $4.92 billion, a P/E ratio of 6.11 and a beta of 0.41. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols, S.A. has a 12-month low of $5.79 and a 12-month high of $9.96.

Analyst Ratings Changes

Separately, Morgan Stanley initiated coverage on shares of Grifols in a research note on Wednesday, February 12th. They set an "overweight" rating for the company.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.